Font Size

Award for Dr. Linn-Rasker for her contribution to pharmacovigilance

Date: 12 October 2016

During the symposium in honor of the 25th anniversary of the Netherlands Pharmacovigilance Centre Lareb rheumatologist Dr. Linn-Rasker received an award for her contribution to drug safety.

This price is for the first reporter of a special or impressive new adverse drug reaction or who has otherwise contributed to the safer use of drugs.

Dr. Linn Rasker, a rheumatologist, did the first report on the occurrence of Merkel cell carcinoma with the use of adalimumab. She also published about this in the Dutch Journal of Medicine.

Adalimumab is a drug which among other things is used in the treatment of rheumatoid arthritis, inflammation of the spinal column (ankylosing spondylitis), Crohn's disease and psoriasis. Merkel cell carcinoma is a rare and aggressive form of skin cancer. The possible emergence of a Merkel cell carcinoma has been recognized as a rare adverse drug reaction in the information leaflet.

Reports of adverse drug reactions from health care professionals and patients once again show their value in pharmacovigilance.

Subscribe to our newsletter